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in azidothymidine (AZT)-induced toxicity of isolated rat
liver mitochondriaJolanta Pupure 1*, Maria A. S. Fernandes 2, Maria S. Santos 2, Anto´nio J. M. Moreno 2,
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3Latvian Institute of Organic Synthesis, Riga, Latvia
4Department of Biochemistry, Faculty of Medicine, University of Coimbra, Coimbra, PortugalPreviously mildronate, an aza-butyrobetaine derivative, was shown to be a cytoprotective drug, through its mechanism of
action of inhibition of carnitine palmitoyltransferase-1, thus protecting mitochondria from long-chain fatty acid accumu-
lation and subsequent damage. Recently in an azidothymidine (AZT)-induced cardiotoxicity model in vivo (in mice), we
have found mildronate’s ability of protecting heart tissue from nuclear factor kB abnormal expression. Preliminary data also
demonstrate cerebro- and hepatoprotecting properties of mildronate in AZT-toxicity models. We suggest that mildronate may
target its action predominantly to mitochondria. The present study in isolated rat liver mitochondria was designed to clarify
mitochondrial targets for mildronate by using AZT as a model compound. The aim of this study was to investigate: (1)
whether mildronate may protect mitochondria from AZT-induced toxicity; and (2) which is the most critical target in
mitochondrial processes that is responsible for mildronate’s regulatory action. The results showed that mildronate protected
mitochondria from AZT-induced damage predominantly at the level of complex I, mainly by reducing hydrogen peroxide
generation. Significant protection of AZT-caused inhibition of uncoupled respiration, ADP to oxygen ratio, and transmem-
brane potential were also observed. Mildronate per se had no effect on the bioenergetics, oxidative stress, or permeability
transition of rat liver mitochondria. Since mitochondrial complex I is the first enzyme of the respiratory electron transport
chain and its damage is considered to be responsible for different mitochondrial diseases, we may account for mildronate’s
effectiveness in the prevention of pathologies associated with mitochondrial dysfunctions. Copyright# 2008 John Wiley &
Sons, Ltd.key words— mildronate; AZT; mitochondria; respiratory complex I; rat liverINTRODUCTION
Mitochondria play an essential role in the cell by
providing energy and controlling cell survival.1
Therefore, mitochondrial dysfunction can cause a
wide range of diseases, such as diabetes and obesity,2
neurodegenerative diseases, such as Parkinson’s and
Alzheimer’s,3 as well as ophtalmoplegia4 and* Correspondence to: Dr J. Pupure, Department of Pharmacology,
Faculty of Medicine, University of Latvia, 1A Sarlotes St., LV-1001,
Riga, Latvia. Tel: þ371 263 52443; Fax: þ371 736 6306.
E-mail: pupure@e-apollo.lv
Copyright # 2008 John Wiley & Sons, Ltd.myopathy.5 Furthermore, hundreds of mitochondrial
proteins vary in amounts from tissue to tissue,
suggesting that the control of mitochondrial gene
activity is very complex.6 The main causes of
mitochondrial dysfunction are mutations of mito-
chondrial DNA3 and interruption of the homeostatic
loop between mitochondria and the reactive oxygen
species generated by mitochondrial respiratory
chain activity.7
Supporting the strategy that mitochondrial dysfunc-
tion may be protected/reversed by drugs capable of
regulatingand improving mitochondrial processes,8 we
suggested that mildronate, a drug of aza-butyrobetaineReceived 14 February 2008
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MILDRONATE PROTECTS MITOCHONDRIAL TOXICITY 621class,maytargetmitochondria.Thissuggestionisbased
on previous data showing that mildronate is capable of
protecting mitochondrial membranes from damage by
free fatty acids (FFAs),9 as well as from AZT-induced
morphological changes and activation of nuclear factor
kBp65 in mice cardiac tissue.10
Furthermore, it was also shown that mildronate
decreases the concentration of lactic acid and increases
ATP level in cardiac tissue after coronary artery
occlusion;11 as well as preventing the drop of ATP
content during hypoxia of isolated rat heart .12 A
plausible mechanism to explainmildronate’sprotective
action is related to its ability to regulate carnitine levels
by acting as a competitive inhibitor of gamma-
butyrobetaine (GBB) hydroxylase,13,14 thus inhibiting
GBB transformation to carnitine. In fact, in rat liver
mitochondria, mildronate was found to inhibit carni-
tine-palmitoyltransferase-1, thus protecting against
long-chain fatty acid accumulation and subsequent
damage of mitochondrial membranes.9
In order to gain some insight into understanding of
mildronate’s mechanism of action, particularly at the
level of mitochondrial functions, we investigated its
influence on azidothymidine (AZT) hepatotoxicity,
using this drug as a mitochondria-compromising
agent. AZT is a well-known anti-HIV drug of
nucleoside reverse transcriptase class, used as one
of the main drug components of highly active
anti-retroviral therapy (HAART). The toxic influences
on mitochondria are widely described: AZT depleted
mitochondrial DNA in isolated rat liver and heart
mitochondria,15 caused dysfunction of mitochondrial
respiratory chain, leading to anaerobic ATP synthesis
and lactic acid production,16 histopathological and
ultrastructural changes of mitochondria,17 and oxi-
dative stress by activation of reactive oxygen
species.18 These events are considered as the
main causes leading to severe side effects such as
hepatotoxicity,19 cardiac and skeletal muscle pathol-
ogies, peripheral neuropathy, pancreatitis, lactic
acidosis, and bone marrow suppression.18
In the present study, we examined the influence of
mildronate in the AZT-toxicity model of isolated rat
liver mitochondria.MATERIALS AND METHODS
Chemicals
The chemicals were from Sigma Chemical Company
(St Louis, MO, USA): ADP, rotenone (inhibitor
of complex I), p-trifluoromethoxyphenylhydrazoneCopyright # 2008 John Wiley & Sons, Ltd.(FCCP, uncoupler), antimycin A (inhibitor of complex
III), cyclosporine A (inhibitor of mitochondrial
permeability transition (MPT)), catalase (anti-oxidant
enzyme), components of media. Azidothymidine
(30-azido-30-deoxythymidine, AZT, zidovudine, retro-
vir, 100 mg capsules) from Wellcome Foundation Ltd.,
London; mildronate [3-(2,2,2-trimethylhydrazinium)
propionate dihydrate] from the Joint Stock Company
‘‘Grindex’’ (Riga, Latvia).
A solution of AZT was prepared as follows: the
content of one 100 mg capsule of AZT was suspended
in 5 ml of H2O in a glass centrifuge tube overnight.
Then, the suspension was centrifuged at 3000 rpm for
10 min, the supernatant was saved and stored in
aliquots of 2 ml each in the cold (48C). The presence of
AZT in the supernatant was confirmed by UV spectra
(200–400 nm) and its concentration was calculated to
be 50 mM using a molar extinction coefficient
(226 nm) of 11 650.20 Mildronate was dissolved in
5 ml of distilled water to obtain 50 mM solution. The
concentrations of the drugs used in this study were 0.1,
0.2, 0.5, 1.5, 2.5, 5, and 10mmol mg1 protein.Animals
Male Wistar rats (250–350 g), were obtained from
Central Vivarium, Faculty of Medicine, University of
Coimbra, Coimbra, Portugal, housed at 22 28C
under artificial light with a 12 h light/dark cycle and
with access to water and food ad libitum. The
experiments were carried out in accordance with the
National Requirements for Vertebrate Animal
Research and with the European Convention for the
Protection of Animals used for Experimental and
other Scientific Purposes.Isolation of rat liver mitochondria
Rat liver mitochondria were isolated from male
6-week-old Wistar rats by differential centrifugation
according to conventional methods.21 After washing,
the pellet was gently re-suspended in the washing
medium at a protein concentration of about
50 mg ml1. Protein content was determined by the
biuret method,22 using bovine serum albumin as a
standard.
Measurement of respiratory activities
Oxygen consumption was monitored polarographi-
cally with a Clark-type electrode, in a closed glassCell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
622 j. pupure ET AL.chamber equipped with magnetic stirring, thermo-
stated at 308C. Mitochondria (1 mg protein) were
incubated in 1 ml of medium containing 250 mM
sucrose, 10 mM Hepes (pH 7.2), 20 mM KCl,
5 mM K2HPO4, and 2 mM MgCl2, supplemented with
2mM rotenone (only when succinate was used as
respiratory substrate), in the presence and absence of
AZT, mildronate, and mildronateþAZT, then ener-
gized with either 10 mM glutamate/5 mM malate or
10 mM succinate. To induce state 3 respiration, ADP
(100–200 nmol mg1 protein) was added. FCCP-
stimulated respiration (uncoupled respiration) was
initiated by the addition of 1mM FCCP. Respiration
rates were calculated by assuming that the saturation
oxygen concentration was 230 nmol O2 ml
1. Control
values are expressed in nmol O2 per mg protein per
minute. The respiratory control ratio (RCR), which is
calculated by the ratio between state 3 (consumption
of oxygen in the presence of substrate and ADP) and
state 4 (consumption of oxygen after ADP phos-
phorylation), is an indicator of mitochondrial mem-
brane integrity. ADP/oxygen ratio (ADP/O) is
expressed as the ratio between the amount of the
added ADP and the consumed oxygen during state-3
respiration, and served as index of oxidative phos-
phorylation efficiency. Both RCR and ADP/O were
calculated according to a previously described
method.23Measurement of mitochondrial transmembrane
potential
The mitochondrial transmembrane potential (DC) was
measured indirectly based on the activity of the
lipophilic cation tetraphenylphosphonium (TPPþ)
using a TPPþ-selective electrode, as previously
described.24 Mitochondria (1 mg protein) were incu-
bated at 308C, in 1 ml of medium containing 250 mM
sucrose, 10 mM Hepes (pH 7.2), 20 mM KCl,
5 mM K2HPO4, and 2 mM MgCl2, supplemented with
3mM TPPþ and 2mM rotenone (when using succinate
as respiratory substrate), in the absence and presence
of AZT, mildronate, and mildronateþAZT, then
energized with either 10 mM glutamate/5 mM malate
or 10 mM succinate. To induce phosphorylation, ADP
(100–200 nmol mg1 protein) was added. No correc-
tion was made for the ‘‘passive’’ binding of TPPþ to
the mitochondria membranes because the purpose
of the experiments was to show relative changes in
potential rather than absolute values. Phosphorylation
time is considered as the time required by mitochon-
dria to phosphorylate all the ADP added. It wasCopyright # 2008 John Wiley & Sons, Ltd.calculated by measuring the time that is needed for
restoration of the membrane potential after a pulse
of ADP by taking into account the recording
speed.
Ca2R-induced mitochondrial permeability
transition (MPT)
To detect Ca2þ-induced MPT, we used oxygen and
TPPþ electrodes and a medium containing 200 mM
sucrose, 10 mM Hepes-Tris (pH 7.4), 1 mM KH2PO4,
10mM EGTA, supplemented with 2mM rotenone, in
the absence and presence of the test compounds.
Mitochondria (1 mg), incubated at 308C in 1 ml of
medium, were energized with 5 mM succinate and
three additions of 20 nmol Ca2þmg1 protein each
were used to induce MPT.25 Control assays, in both the
absence and presence of Ca2þþ 1mM cyclosporin A
(CsA), were also performed.
Hydrogen peroxide generation
Hydrogen peroxide (H2O2) generation was measured
fluorometrically using a modification of the method
previously described.26 Briefly, mitochondria
(0.375 mg) were incubated at 308C in 1.5 ml of
phosphate buffer, pH 7.4, containing 5 mM phosphate,
0.1 mM EGTA, 145 mM KCl, 30 mM Hepes, 0.1 mM
homovallinic acid, and 6 U ml1 horseradish peroxi-
dase (in the presence or absence of inhibitors such as
rotenone,antimycinA,catalase, and the testdrugs).The
reactions were started by adding 10 mM glutamate/
5 mM malate or 10 mM succinate and stopped at 15 min
with 0.5 ml of cold 0.1 M glycine-NaOH (pH 12)
containing 25 mM EDTA. The mitochondrial suspen-
sions were centrifuged at 850 g for 10 min. The enzyme
catalasewasusedasapositivecontrol toconfirmthat the
generated H2O2 is scavenged. The fluorescence of
supernatants was measured at 312 nm as excitation and
420 nm as emission wavelengths. The peroxide
generation was calculated using a standard curve
of H2O2. The standards and samples were incubated
under the same conditions.
Statistical analysis
All the experiments were performed using four
independent mitochondrial preparations. The values
were expressed as mean SEM. Means were com-
pared using one-way ANOVA, post-test Dunnett.
Statistical significance was set at p< 0.05.Cell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
Figure 1. Effects of azidothymidine (AZT), mildronate (MIL), and
MILþAZT on glutamate/malate- (A) and succinate-supported
(B) O2 consumption in state 3, state 4, and FCCP-uncoupled respir-
ation of rat liver mitochondria. Mitochondria were incubated under
standard conditions as described in Section ‘‘Materials and
Methods’’ without (control) or with the indicated concentrations
of AZT, MIL, and MILþAZT. Control values expressed in nmol O2
per mg protein per minute: (A) state 3¼ 46.72 1.54; state
4¼ 9.36 1.01; FCCP¼ 22.07 2.47; (B) state 3¼ 71.34 0.56;
state 4¼ 14.35 0.84; FCCP¼ 68.43 2.41. Results correspond to
the meanSEM of four experiments obtained from different mito-
chondrial preparations. p< 0.05 versus control, $p< 0.05 versus
AZT 10mmol mg1 protein
Figure 2. Effects of azidothymidine (AZT), mildronate (MIL),
and MILþAZT on glutamate/malate- (A) and succinate-supported
(B) respiration indices: respiratory control ratio (RCR) and ADP/O
ratio of rat liver mitochondria without (control) or with the indicated
concentrations of AZT, MIL, and MILþAZT. Mitochondria were
incubated under standard conditions as described in Section
‘‘Materials and Methods’’. Results correspond to the mean SEM
SEM of four experiments obtained from different mitochondrial
preparations. p< 0.05 versus control, #p< 0.05 versus AZT
5mmol mg1 protein, $p< 0.05 versus AZT 10mmol mg1 protein
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Effects of AZT, mildronate, and mildronateRAZT
on mitochondrial bioenergetics
The effects of AZT, mildronate, and AZTþ
mildronate on glutamate/malate- and succinate-
supported respiratory rates characteristic of state 4,
state 3 and uncoupled respiration, as well as,
respiratory indices RCR and ADP/O ratio of rat liver
mitochondria in vitro are depicted in Figures 1 and 2.
State 4 respiration was not affected using either of the
respiratory substrates, whereas state 3 respiration wasCopyright # 2008 John Wiley & Sons, Ltd.inhibited by AZT (10mmol mg1 protein) by 62 and
23% with glutamate/malate and succinate, respect-
ively. Uncoupled respiration supported by glutamate/
malate was also significantly inhibited (by 45%) with
10mmol mg1 protein AZT, whereas uncoupled
respiration supported by succinate was less affected
(by 3%). At the same concentration, AZT significantly
depressed RCR (from about 5 to 3) with glutamate/
malate but not with succinate. The ADP/O ratio was
affected significantly more with glutamate/malate
(46%) than with succinate (23%) as substrate. In
contrast to AZT, mildronate concentrations up to
10mmol mg1 protein, did not affect any of the
parameters reported above using either glutamate/
malate or succinate as the respiratory substrates.Cell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
624 j. pupure ET AL.Combined administration of mildronate with AZT
(both 10mmol mg1 protein) prevented AZT-induced
inhibition of uncoupled respiration and ADP/O with
glutamate/malate, as well as ADP/O depression with
succinate.
The effects of AZT, mildronate, and mildronateþ
AZT on mitochondrial transmembrane potential (DC)
and phosphorylation time supported by glutamate/
malate and succinate are shown in Figure 3 and
Table 1. AZT dissipated DC and increased theFigure 3. Effects of azidothymidine (AZT), mildronate (MIL), and
transmembrane potential (DC). Rat liver mitochondria were incubated i
without (control) or with the indicated concentrations of AZT, MIL, an
malate or 10 mM succinate. 100 nmol mg1 protein ADP was added to i
representative of four experiments obtained from different mitochond
Copyright # 2008 John Wiley & Sons, Ltd.phosphorylation time for both substrates, but
these effects were more pronounced with glutamate/
malate (from about 208 to 196 mV) than with
succinate (from about 215 to 208 mV). The
phosphorylation time was increased by 77% for
glutamate/malate (Figure 3A and Table 1) and by 36%
for succinate (Figure 3B and Table 1). Mildronate did
not significantly affect DC and phosphorylation time
dependent on glutamate/malate or succinate. Com-
bined administration of mildronate with AZT (bothMILþAZT on glutamate/malate- (A) and succinate-supported (B)
n reaction medium as described in Section ‘‘Materials and Methods’’
d MILþAZT. Reactions were started with 10 mM glutamate/5 mM
nduce phosphorylation. The traces represent typical direct recordings
rial preparations
Cell Biochem Funct 2008; 26: 620–631.
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Figure 3. (Continued)
MILDRONATE PROTECTS MITOCHONDRIAL TOXICITY 62510mmol mg1 protein) prevented AZT-induced inhi-
bition of repolarization with glutamate/malate
(Figure 3A and Table 1).
Effects of AZT, mildronate, and mildronateRAZT
on hydrogen peroxide generation
The effects of AZT, mildronate, and mildronateþ
AZT on hydrogen peroxide generation by rat liver
mitochondria in vitro were studied using bothCopyright # 2008 John Wiley & Sons, Ltd.glutamate/malate and succinate as respiratory sub-
strates (Figure 4). In the absence of mildronate and
AZT, the H2O2 generated by glutamate/malate-
respiring mitochondria significantly increased when
mitochondria were treated with rotenone (inhibitor of
complex I) alone and with rotenoneþ antimycin A
(inhibitor of complex III, Figure 4A). The elevated
production of H2O2 was reduced by catalase to levels
below those observed under basal conditions (mito-
chondria in the presence of glutamate/malate), asCell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
Table 1. Effects of AZT (azidothymidine), MIL (mildronate), and AZTþMIL on glutamate/malate- (A) or succinate-dependent
(B) transmembrane potential (DC) and phosphorylation of rat liver mitochondria at the different indicated situations
Compound (mmol mg1 protein)
DC (mV)
Phosphorylation
time (s)
Glutamate/malate
energization ADP depolarization Repolarization
Control (0) 212.9 1.2 24.2 0.9 206.0 1.4 40.5 1.0
AZT (2.5) 218.5 0.5 23.2 1.2 209.8 2.0 44.0 1.5
AZT (5) 209.0 7.4 21.5 0.5 191.0 3.0 73.5 11.9
AZT (10) 202.0 6.0 24.8 3.6 182.0 5.2 172.5 13.4
MIL (2.5) 216.5 0.5 22.3 3.6 211.8 0.5 32.1 2.0
MIL (5) 214.4 2.5 25.5 1.5 208.0 1.0 39.0 1.5
MIL (10) 212.5 0.5 26.4 0.9 207.5 1.5 39.8 6.8
AZTþMIL (10þ 10) 212.0 1.0 26.7 0.4 200.3 1.3#$ 98.6 6.7
Compound (mmol mg1 protein)
DC (mV)
Phosphorylation time (s)Succinate energization ADP depolarization Repolarization
Control (0) 213.9 0.6 21.3 0.9 212.5 0.7 41.3 3.2
AZT (2.5) 213.0 1.4 19.6 0.7 210.6 0.7 41.3 3.8
AZT (5) 219.0 2.0 19.5 0.6 208.8 0.9 53.3 0.8
AZT (10) 214.5 0.5 17.7 1.3 205.3 0.6 64.5 3.8
MIL (2.5) 214.3 1.8 18.9 1.2 212.7 0.9 34.5 1.5
MIL (5) 221.0 1.0 22.7 1.2 216.8 0.5 42.0 3.0
MIL (10) 217.0 3.0 22.5 1.2 212.3 1.9 51.0 3.2
AZTþMIL (10þ 10) 214.0 1.0 21.0 1.4 204.3 0.5 57.0 1.2
Rat liver mitochondria were incubated in reaction medium without (control) or with the indicated concentrations of AZT, MIL, and
AZTþMIL. The results are mean valuesSEM of four independent experiments. p< 0.05 versus control; #p< 0.05 versus AZT
5mmol mg1 protein; $p< 0.05 versus AZT 10mmol mg1 protein.
626 j. pupure ET AL.expected. AZT concentrations up to 10mmol mg1
protein significantly increased H2O2 generation by
glutamate/malate-respiring mitochondria in the
absence and presence of rotenone, but were without
significant effect in the presence of rotenoneþ
antimycin A. A maximal increase of H2O2 generation
(of about 70%) was observed at 10mmol mg1 protein
AZT for both conditions. Mildronate concentrations
up to 10mmol mg1 protein did not significantly
affect H2O2 generation under any of the conditions
used (Figure 4A). However, co-administration of
mildronate with AZT (both 10mmol mg1 protein)
significantly reduced H2O2 generation promoted by
AZT alone either under basal conditions (by about
55%) or in mitochondria treated with rotenone (by
about 34%, Figure 4A). Similar to glutamate/malate,
succinate-respiring mitochondria (in the presence of
rotenone, Figure 4B) responded to treatment with
antimycin A with maximally stimulated H2O2 pro-
duction. This effect was reduced by catalase to levels
below those observed under basal conditions (mito-
chondria in the presence of rotenone). A maximal
increase of H2O2 generation (by about 58%) wasCopyright # 2008 John Wiley & Sons, Ltd.observed at 10mmol mg1 protein AZT with succi-
nate-respiring mitochondria under basal conditions.
No effect was noted in mitochondria treated with
rotenoneþ antimycin A (Figure 4B). Mildronate
concentrations up to 10mmol mg1 protein did not
significantly affect the H2O2 generation either under
basal conditions or in mitochondria treated with
rotenoneþ antimycin A (Figure 4B). In contrast to
glutamate/malate-respiring mitochondria, combined
administration of mildronate and AZT (both
10mmol mg1 protein) did not significantly
reduce H2O2 generation promoted by AZT alone in
succinate-respiring mitochondria (basal conditions).Effects of AZT, mildronate, and mildronateRAZT
on Ca2R-induced mitochondrial permeability
transition (MPT)
Figure 5 shows the effects of AZT, mildronate, and
mildronateþAZT on the MPT in vitro. This effect was
evaluated by measuring the decline in mitochondrialCell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
Figure 4. Effect of azidothymidine (AZT), mildronate (MIL), and
MILþAZT on hydrogen peroxide production of rat liver mitochon-
dria. Mitochondria were incubated under standard conditions as
described in Section ‘‘Materials and Methods’’ with glutamate/
malate (A) or succinate (B) as respiratory substrates under the
following conditions: without inhibitors (dotted bars); with 2mM
rotenone (Rot, black bars); rotenone and 10mM antimycin A
(RotþAA, white bars); and rotenone, antimycin A and 643 U ml1
catalase (RotþAAþCAT, dashed bars). The results correspond to
the meanSEM of four experiments obtained from different mito-
chondrial preparations. p< 0.05 versus control, #p< 0.05 versus
AZT 10mmol mg1 protein
MILDRONATE PROTECTS MITOCHONDRIAL TOXICITY 627transmembrane potential (DC) and the increase in
oxygen consumption which are typical phenomena that
follow the induction of MPT. Under control conditions,
the addition of 5 mM succinate produced a DC of
217 mV (negative inside mitochondria), corre-
sponding to the respiratory state 4. The first pulse of
20 nmolCa2þmg1protein ledtoarapiddepolarization
(decrease of DC) followed by a small repolarization
(recovery of DC). The depolarization was due to the
entry of Ca2þ into the electronegative mitochondrial
matrix, followed by the efflux of Hþ for restoring the
DC.Consequently, respiratory state 4 increased from13
to 17 nmol O2 mg
1 protein min1. However, a second
and third pulse of 20 nmol Ca2þmg1 protein led to a
total depolarization of mitochondria and to a maximalCopyright # 2008 John Wiley & Sons, Ltd.increase of respiratory state 4 (60 nmol O2 min
1 mg1
protein).
Incubation of mitochondria with AZT concen-
trations up to 5mmol mg1 protein or with mildronate
concentrations up to 10mmol mg1 protein, for 2 min
before energizing with succinate, did not affect
significantly the capacity of mitochondria to
accumulate Ca2þ (Figure 5). However, at concen-
trations 5–10mmol mg1 protein AZT reduced the
capacity of mitochondria to accumulate Ca2þ to
40 nmol mg1 protein. Mildronate, in combination
with AZT, reversed this effect to control values
(60 nmol mg1 protein, Figure 5). Incubation of
mitochondria with 0.85mM cyclosporin A, a specific
inhibitor of MPT,27 for 2 min before energizing with
succinate, either in the absence or presence of AZT or
mildronate totally blocked mitochondrial depolariz-
ation and increased respiratory state 4 (results not
shown), showing that these effects have been induced
by MPT.
DISCUSSION
This study was devoted to the clarification of the
mechanism of action of mildronate (MET-88), an
aza-butyrobetaine derivative, which was previously
shown as a cytoprotective agent capable of regulating
the cardiovascular system and cardiac functions.11,12 It
is suggested that mildronate’s protective action is based
on its ability to inhibit carnitine palmityoiltransferase-1
activity thus decreasing the amount of activated FFAs in
mitochondria.9 SinceactivatedFFAspossessdetergent-
like activity damaging mitochondrial membranes, we
suggest that mitochondria may serve as the target for
midronate’s cytoprotective action. Thus, for the present
study we have chosen the model compound AZT, a
well-known mitochondria-compromising anti-HIV
drug. Previously, several studies have demonstrated
that AZT causes changes in mitochondrial structure,
alters respiratory chain enzyme activity, lowers
mitochondrial ATP, activates reactive oxygen species,
increases lactic acid production, and causes loss of
mitochondrial DNA and cytochrome C.28–30 Our
previous experiments in AZT-induced cardiotoxicity
model inmice,10 aswell aspreliminarystudies inneuro-
and hepatotoxicity states (unpublished data) demon-
strated high anti-inflammatory and anti-apoptotic
effects of mildronate, suggesting that it may regulate
cellular damages initiated by AZT at least in part at the
level of mitochondria.
Our present study was performed in an isolated rat
liver mitochondria. The results obtained have provided
evidence that mildronate (10mmol mg1 protein)Cell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
Figure 5. Effects of azidothymidine (AZT), mildronate (MIL), and MILþAZT at indicated concentrations on mitochondrial permeability
transition pore induction: susceptibility to Ca2þ (20 nmol mg1 protein) addition. Freshly isolated rat liver mitochondria (1 mg) in 1 ml of
standard medium supplemented with 3mM TPPþ were energized with 5 mM succinate (as described in Section ‘‘Materials and Methods’’).
The traces represent typical direct recordings representative of four experiments obtained from different mitochondrial preparations
628 j. pupure ET AL.prevented AZT-induced mitochondrial toxicity. It
remarkablyreducedAZT-causedincreaseinproduction
of H2O2 by 58% in basal conditions and by 34% in the
presence of rotenone, an inhibitor of complex I. Since
AZT-induced H2O2 production also under basal
conditions, thus showing pro-oxidant properties, we
suggest that theabilityofattenuatingtheAZTeffectmay
be provided via mildronate’s anti-oxidant properties.
Our data are in good agreement with other resultsCopyright # 2008 John Wiley & Sons, Ltd.reporting that mildronate may protect heart tissue
against the H2O2-induced derangement in energy
metabolism.31 Our data also showed that mildronate
prevented the AZT-induced inhibition of uncoupled
respiration and ADP/O ratio, and recovery of trans-
membrane potential (by 21, 36, and 9%, respectively)
with glutamate/malate, thus providing the electron flow
in the respiratory chain at the level of complex I, with
subsequent improvement of the efficiency of state 3Cell Biochem Funct 2008; 26: 620–631.
DOI: 10.1002/cbf
MILDRONATE PROTECTS MITOCHONDRIAL TOXICITY 629respiration,RCR,mitochondrial transmembranepoten-
tial, and phosphorylation. However, in our experiments
AZT-inducedMPTwasweaklyexpressed(inductionby
33%); mildronate normalized this effect to control
levels. Nevertheless, since it is known that activation of
MPT compromises the normal integrity of the
mitochondrial outer membrane, thus influencing inner
membrane leading to the release of cytochrome C,
activation of caspase family proteins and subsequent
apoptosis, as well as metabolic changes resulting in
subsequent necrosis,32 one may suggest that mildronate
influences oxidative stress. Moreover, our previous
data10 obtained inmice cardiac tissuedemonstrated that
mildronate protected AZT-increased expression of
redox-sensitive nuclear transcription factor kBp65
(NF-kBp65), which can be activated by reactiveoxygen
species, and plays a critical role in immune and
inflammatory responses.33 Other data showed that
mildronate improved cardiac sarcoplasmic
reticulum Ca2þ uptake activity in rats with congestive
heart failure following myocardial infarction.11 There-
fore, previous and present data demonstrating mildro-
nate’s activity to inhibitH2O2 production and MPT pore
opening indicate mildronate’s ability to halt apoptotic
and necrotic processes at their early stages. It must be
also noted that mildronate per se did not affect
mitochondrial function either in glutamate/malate or
succinate respiration.
In our experiments, we were faced with the fact that
AZT caused strong alterations in mitochondrial
function at relatively high concentrations of the range
of 5–10mmol mg1 protein. It inhibited bioenergetics
(namely uncoupled respiration, respiration in state 3,
RCR, ADP/O ratio, mitochondrial transmembrane
potential, and phosphorylation) and considerably (by
44–64% compared to control) increased H2O2 pro-
duction with glutamate/malate (respiratory substrate
for complex I), indicating AZT’s severe effect at the
level of complex I. At the highest concentration used
(10mmol mg1 protein), AZT also increased H2O2
production when succinate was used as substrate, thus
showing the influence of AZT on complex II. AZT had
no effect on complex III, since it did not affect H2O2
formation in mitochondria inhibited with rotenone
(inhibitor of complex I)þ antimycin A (inhibitor of
complex III). Our data are in good agreement with
findings obtained in other studies which revealed
inhibitory effects of AZT at concentrations 5–15 mM
on bioenergetics at the level of complex I in rat liver,
kidney, skeletal, and heart muscle mitochondria.34
AZT had no effect at the level of complex II on
mitochondrial bioenergetics of rat liver and kidney,34
and heart.35 AZT also induced an increase in H2O2Copyright # 2008 John Wiley & Sons, Ltd.production in rat peritoneal macrophages,36 and in
AZT-treated mice muscle mitochondria,37 as well as
inhibition of NADH cytochrome C reductase, an
enzyme of complex I.38,39 Nevertheless, in rat heart
mitochondria, different data were obtained: no
influence on bioenergetics and Ca2þ loading capacity
at 0.01 mM, while inhibition of glutamate/malate-
dependent RCR with corresponding increase in the
rate of state 4 at 0.1 mM were found.35 Recently, it was
shown that the AZT inhibitory effect on complex I is
due to the inhibition of cAMP-dependent phosphoryl-
ation of complex I.40
We suggest that the high AZT concentrations found
to be active in our mitochondrial studies can be
considered as relevant, since AZT is used for the
treatment of HIV-infected AIDS patients at doses of
about 500–1500 mg daily for a long survival period.41
The same concerns apply to mildronate, which in the
present study was protective at concentrations
5–10mmol mg1 protein, and its clinical doses are
known to amount to 1000 mg daily used at least for a
3-month period.42
In conclusion, our present data have demonstrated
for the first time that mildronate, a representative of
the aza-butyrobetaine class, may protect the
AZT-induced H2O2 formation in isolated rat liver
mitochondria at the level of complex I, indicating
mildronate as a mitochondria-targeted drug. Also, its
anti-oxidant properties are essential for halting
reactive oxygen species-induced oxidative stress
reactions leading to cell death. Since mitochondrial
complex I is the first enzyme of the respiratory
electron transport chain and its deterioration is
considered as a crucial cause for neurodegenerative
diseases, such as Parkinson’s and Alzheimer’s, as well
as diabetes type II, anti-HIV therapy-induced mito-
chondrial disorders, and others, one may suggest
mildronate’s usefulness in the treatment of different
mitochondrial diseases.
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